放疗联合吉非替尼治疗Ⅳ期非小细胞肺癌疗效分析  

Curative effect of eradiation combined with targeted therapy of gefitinib on patients with stage IV NSCLC

作　　者：祖卫 张素英[1] 

机构地区：[1]保定市第三医院/肿瘤医院放疗科,河北保定071000

出　　处：《现代肿瘤医学》2010年第11期2150-2151,共2页Journal of Modern Oncology

摘　　要：目的:评价放疗联合吉非替尼治疗非小细胞肺癌的疗效及安全性。方法:26例非小细胞肺癌患者,其中女性20例,男性6例,病理诊断均为腺癌,所有患者均伴有骨或脑单发或多发转移。放疗部位包括肺原发灶及骨或脑转移灶,肺原发灶放疗剂量50-60Gy,脑转移灶接受全脑放疗30-40Gy,部分患者采用适形放疗加量10-20Gy。骨转移灶放疗剂量40-46Gy。放疗期间及结束后服用吉非替尼250mg/qd,直至肿瘤进展。结果:所有患者放疗期间均完成吉非替尼治疗,3例出现腹泻,7例伴发呕吐,12例合并皮疹,7例皮肤干燥。放疗联合吉非替尼治疗期间症状缓解率92%,ECOG评分由放疗前平均3分提高到放疗后2分。原发灶有效率(CR+PR)88.5%(23/26)。转移灶有效率(CR+PR)73.1%(19/26)。最长随访时间20个月,中位生存时间(MST)9.5个月,疾病进展时间(TTP)6.2个月。1年生存率39.1%(9/23)。结论:Ⅳ期非小细胞肺癌放疗联合吉非替尼治疗是有效而安全的,对生存时间的影响需进一步观察。Objective：To evaluate the efficacy and safety of radiation combined with gefitinib on patients with stage IV non-smal cell lung cancer（NSCLC）.Methods：Among 26 patients there were 20 female and 6 male patients with NSCLC,all 26 patients were adenocarcinoma.The median age was 52 years and all patiens suffered from single or multiple bone metastasis or brain metastasis.Radiation fields included primary lung cancer sites and bone metastasis or brain metastasis.The dose of primary lung cancer sites was 50-60Gy.Whole brain radiation dose was 30-40Gy boosted by conformal radiotherapy 10-20Gy,40-46Gy delivered to bone metastasis.Gefitinib 250mg were given.Results：All patients can complete the combined therapy,3 of them susuffered from diarrhea,7 with emesia and 12 with erythra,7 with dry skin.92% of them achieved remission during radiation combined with the targeted therapy.The score of ECOG was improved from 3 to 2.The effective rate of primary tumor was 88.5%,metastasis 73.1%.The follow-up time was 20 months.The median survival time was 9.5 months.TTP 6.2 months One-year survrval rate 39.1%.Conclusion：Palliative radiation combined with targeted therapy of gefitinib is a effective and safe therapy for the patients with stage IV NSCLC.

关 键 词：放疗 吉非替尼 非小细胞肺癌 

分 类 号：F734.2[经济管理—产业经济]